Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

151
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
151
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

142
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

136
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
136

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

microRNAs as epigenetic biomarkers for CTEPH: a case-control study towards personalised medicine.

ERJ open research·2026
Same author

Evaluation of microbial-derived metabolites in patients with acute pulmonary embolism: findings from the MICTEP study.

ERJ open research·2025
Same author

Role of Extracellular Vesicles in Chronic Post-Embolic Pulmonary Hypertension: Data from an Experimental Animal Model and Patients.

Biomedicines·2025
Same author

Gender Bias in Clinical Trials of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Journal of diabetes research·2025
Same author

Systematic evaluation of subgroup analyses of inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.

PloS one·2025
Same author

Impact of Residual Vein Venous Thrombosis in Consecutive Patients with Cancer-Associated Thrombosis Treated with Tinzaparin-A Cohort Study.

Cancers·2024

Related Experiment Video

Updated: Jun 9, 2025

Author Spotlight: Exploring Breathing Techniques and Digital Solutions for Enhancing Running Performance
06:26

Author Spotlight: Exploring Breathing Techniques and Digital Solutions for Enhancing Running Performance

Published on: September 27, 2024

386

Smartphone Apps for Pulmonary Hypertension: Systematic Search and Content Evaluation.

Nerea Báez Gutiérrez1, Héctor Rodríguez Ramallo2, Elva María Mendoza-Zambrano3

  • 1Pharmacy Department, Hospital Universitario Virgen Macarena, Seville, Spain.

JMIR Mhealth and Uhealth
|October 30, 2024
PubMed
Summary

Mobile health apps for pulmonary hypertension (PH) are emerging, offering acceptable quality but needing refinement. Health care professional involvement significantly improves app quality, emphasizing the need for clinical validation and patient-centered design.

Keywords:
appapp developmentchronic conditionclinical validationeHealthevaluationhypertensionmHealthmobile appsmobile health appmonitoringpulmonarypulmonary hypertensionsmartphonesystematic search

More Related Videos

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Subjective Refraction Test Using a Smartphone for Vision Screening
05:36

Subjective Refraction Test Using a Smartphone for Vision Screening

Published on: October 18, 2024

615

Related Experiment Videos

Last Updated: Jun 9, 2025

Author Spotlight: Exploring Breathing Techniques and Digital Solutions for Enhancing Running Performance
06:26

Author Spotlight: Exploring Breathing Techniques and Digital Solutions for Enhancing Running Performance

Published on: September 27, 2024

386
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Subjective Refraction Test Using a Smartphone for Vision Screening
05:36

Subjective Refraction Test Using a Smartphone for Vision Screening

Published on: October 18, 2024

615

Area of Science:

  • Medical Informatics
  • Digital Health
  • Pulmonary Medicine

Background:

  • Pulmonary hypertension (PH) is a chronic condition requiring ongoing patient and healthcare professional (HCP) education and management.
  • Smartphone-based mobile health (mHealth) applications offer potential for improved PH monitoring and management.

Purpose of the Study:

  • To identify and evaluate the quality of free mHealth apps for pulmonary hypertension (PH) available to patients and HCPs.
  • To assess changes in app availability and quality between 2022 and 2023.

Main Methods:

  • Systematic search of free PH apps on Android and iOS platforms from a Spanish IP address in October 2022 and 2023.
  • Independent app analysis by two reviewers using the Mobile Application Rating Scale (MARS) framework.
  • Statistical comparison of MARS scores using Mann-Whitney U tests.

Main Results:

  • 21 unique PH apps were identified across both years; only 7 were updated between 2022 and 2023.
  • Overall mean MARS quality was acceptable (3.1 in 2022, 3.3 in 2023), with functionality scoring highest and subjective quality lowest.
  • iOS apps outperformed Android apps, and apps developed with HCP involvement showed significantly higher quality.

Conclusions:

  • Current mHealth apps for PH are in early development, with generally acceptable but unrefined quality.
  • HCP involvement is crucial for enhancing app quality and reliability.
  • A need exists for continuous innovation, patient input, and rigorous clinical validation for effective PH mHealth integration.